Skip to content

Study · Randomized controlled trial · n = 50 · 2012

6 results

Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis.

Michalska D, Luchavova M, Zikan V, Raska I Jr, Kubena AA, Stepan JJ

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA17 Mar 2012Cited by 44 (Europe PMC)

PMID22426952 (opens in a new tab)DOI10.1007/s00198-012-1955-4 (opens in a new tab)PepBankPUB-22426952
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women with osteoporosis, morning teriparatide produced greater lumbar spine BMD gains than evening dosing.

    In plain wordsMorning teriparatide increased spine bone density more than evening teriparatide in women with osteoporosis.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar spine BMD by dosing time
    Study

    n = 50

    Comparator
    Evening teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · 12 monthsAs given in this study (human).

    Measurements

    BMD increase
    9.1%
    morning
    BMD increase
    4.8%
    evening

    Source sentences

    Summary
    After 12 months, the lumbar spine BMD grew markedly (p < 0.001) with a significantly greater increase in the morning arm compared to the evening arm (9.1% vs. 4.8%, respectively, p < 0.05).
    1 context sentence
    Summary · context
    Fifty women with established postmenopausal osteoporosis were randomized to 12-month treatment with 20 μg of TPTD, administered daily in the morning or in the evening.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women, distal radius BMD decreased in both dosing groups without a difference between morning and evening teriparatide.

    In plain wordsForearm bone density decreased in both groups, with no difference between morning and evening teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeDistal radius BMD by dosing time
    Study

    n = 50

    Comparator
    Evening teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    The BMD at the distal radius significantly decreased (p < 0.001), with no differences between the arms.
    1 context sentence
    Summary · context
    Fifty women with established postmenopausal osteoporosis were randomized to 12-month treatment with 20 μg of TPTD, administered daily in the morning or in the evening.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women receiving morning or evening teriparatide, proximal femur BMD did not significantly change.

    In plain wordsHip bone density did not significantly change from baseline in women receiving morning or evening teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeProximal femur BMD
    Study

    n = 50

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · 12 monthsAs given in this study (human).

    Source sentences

    Summary
    The BMD at proximal femur did not change significantly.
    1 context sentence
    Summary · context
    Fifty women with established postmenopausal osteoporosis were randomized to 12-month treatment with 20 μg of TPTD, administered daily in the morning or in the evening.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women, bone turnover markers increased from baseline at 6 months across teriparatide dosing groups.

    In plain wordsBone turnover markers increased from baseline at 6 months across morning and evening teriparatide groups.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone turnover markers at 6 months
    Study

    n = 50

    Comparator
    Baseline
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · 6 monthsAs given in this study (human).

    Source sentences

    Summary
    After 6 months, the BTMs were significantly increased compared with baseline (p < 0.001).
    2 context sentences
    Summary · context
    The BMD and serum concentrations of C-terminal telopeptide of type I collagen, N-terminal propeptide of type I procollagen (PINP), and tartrate-resistant acid phosphatase isoform 5b (TRAP 5b) were measured at baseline, after 6 and 12 months.
    Summary · context
    Fifty women with established postmenopausal osteoporosis were randomized to 12-month treatment with 20 μg of TPTD, administered daily in the morning or in the evening.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women, evening teriparatide produced a greater PINP increase than morning dosing.

    In plain wordsEvening teriparatide increased the PINP bone marker more than morning teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreasePINP increase by dosing time
    Study

    n = 50

    Comparator
    Morning teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · 6 monthsAs given in this study (human).

    Measurements

    PINP increase
    358%
    evening
    PINP increase
    215%
    morning

    Source sentences

    Summary
    The increases in the evening arm vs. the morning arm, however, were more pronounced in PINP (+358% vs. +215%, respectively) and in TRAP 5b (+70% vs. +37%, respectively) (both p < 0.05).
    1 context sentence
    Summary · context
    Fifty women with established postmenopausal osteoporosis were randomized to 12-month treatment with 20 μg of TPTD, administered daily in the morning or in the evening.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In postmenopausal women, evening teriparatide produced a greater TRAP 5b increase than morning dosing.

    In plain wordsEvening teriparatide increased the TRAP 5b bone marker more than morning teriparatide.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseTRAP 5b increase by dosing time
    Study

    n = 50

    Comparator
    Morning teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg/day · 6 monthsAs given in this study (human).

    Measurements

    TRAP 5b increase
    70%
    evening
    TRAP 5b increase
    37%
    morning

    Source sentences

    Summary
    The increases in the evening arm vs. the morning arm, however, were more pronounced in PINP (+358% vs. +215%, respectively) and in TRAP 5b (+70% vs. +37%, respectively) (both p < 0.05).
    1 context sentence
    Summary · context
    Fifty women with established postmenopausal osteoporosis were randomized to 12-month treatment with 20 μg of TPTD, administered daily in the morning or in the evening.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.